close
New CDMO acquisition for Keensight Capital
News

New CDMO acquisition for Keensight Capital

New CDMO acquisition for Keensight Capital

Keensight Capital, a leading Paris-based private equity managers dedicated to pan-European Growth Buyout investments, has just acquired Infarco’s majority stake in 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics. Founded in 2006 and based near Pamplona, Spain, the company has experienced a 23% annual revenue growth over the past 4 years. It offers a complete biologics production service, from preclinical and clinical stages, all the way to full-scale commercial manufacturing.  With more than 240 employees and a wide number of customers located in Europe, North America, Australia and Asia, 3P Biopharmaceuticals has successfully established itself as a recognized European CDMO leader. Keensight Capital will support 3P in its next phase of development, notably by investing in 3P’s production capacity, broadening its service offering and attracting further talents. Keensight expects to be able to leverage its extensive knowledge, expertise and network in the CDMO field, in order to achieve these goals.
Last year, Keensight Capital has already invested in the biologics CDMO market, which is now one of the fastest growing healthcare segments globally with a  market size estimated to be €10bn worldwide and  a 13% annual increase from 2018 to 2022. The company had acquired a majority stake in Biovian, a leading European player in contract manufacturing and development of biopharmaceuticals, alongside the founders and the managers, and Edmond de Rothschild Equity Strategies (ERES) funds. With this operation, Keensight Capital and the ERES funds want to support Biovian to increase its capacities, both in the microbial development space and in the viral vector and gene therapy market.


COMMENTS ARE OFF THIS POST